Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Fig. 3

Patient-specific simulation models were used to predict the expression of PD-L1 (a) and at step 1 of the decision tree, 9 patients (black bars) with predicted PD-L1 expression below 29.0% (bold line) were identified as PD-1 drug non-responders. Patient SA97V5 had a predicted PD-L1 expression of 67.0%. Patient-specific simulation models were used to predict the expression of chemokines used to create a dendritic cell (DC) infiltration index (b). At step 2a of the decision tree, 2 patients (black bars) with index values greater that 60.0% (bold line) were identified as PD-1 drug responders and 2 patients (black bars) with index values less than 20.0% (black line) were identified as PD-1 drug non-responders. Patient SA97V5 had a predicted DC infiltration index of 23.9%

Back to article page